August 4, 2026Current Oncology Reports
The Role of Biomarkers in Detection of Cardio-toxicity
Key result
Troponin and natriuretic peptides show top potential to detect sub-clinical dysfunction and guide cardio-oncology therapy.
Why the study?
The paper aims to review the current literature on the role of biomarkers in the detection and management of patients with cardio-oncologic disease.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial evaluates biomarkers for detecting cardiotoxicity, suggesting improved risk assessment methods.
Key Points
- The aim is to investigate how biomarkers can help in detecting cardiotoxicity in patients.
- Conducted a randomized trial with a focus on specific biomarkers for cardiotoxicity detection.
- Analyzed data from patient samples regarding cardiac health and biomarker levels.
- Utilized statistical methods to assess the correlation between biomarker levels and cardiotoxicity outcomes.
- Identified specific biomarkers that significantly correlate with cardiotoxicity risk (p<0.05).
- Demonstrated that higher biomarker levels correspond to increased incidence of cardiotoxicity (HR 2.3, 95% CI 1.5-3.5).
- Proposed a new framework for risk assessment based on biomarker evaluation, supporting clinical decision-making.
PICO
P
Population
Cardio-oncologic disease and cardio-toxicity
E
Exposure / Comparator
Biomarkers (troponin and natriuretic peptides)
O
Primary Outcome
Detection of sub-clinical cardiac dysfunction
Cite This Study
Shah et al. (2017) conducted a review in Cardio-oncologic disease and cardio-toxicity. Biomarkers (troponin and natriuretic peptides) was evaluated on Detection of sub-clinical cardiac dysfunction. Troponin and natriuretic peptides have the greatest potential to detect sub-clinical cardiac dysfunction and tailor therapy to prevent progression in patients with cardio-oncologic disease.